好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Age of Onset of Cognitive Impairment and the Core Features of Dementia with Lewy Bodies
Aging, Dementia, and Behavioral Neurology
S33 - Aging and Dementia: Non-Alzheimer Dementia (3:42 PM-3:54 PM)
002

To determine whether there are differences in the age of onset of cognitive impairment and the four core features in a large cohort of patients with clinically diagnosed dementia with Lewy bodies (DLB).

A clinical diagnosis of probable DLB requires progressive cognitive impairment and 2 out of 4 core features: cognitive fluctuations, REM sleep behavior disorder (RBD), visual hallucinations (VH) and parkinsonism. The evolution of these cardinal features with respect to each other during the disease course has not been clearly defined.

A cohort of 315 patients with probable DLB who were seen at least twice at the Mayo Clinic Alzheimer’s Disease Research Center were included in the study. To determine differences in the age of onset of each cardinal feature, we compared Kaplan-Meier (KM) survival curves with the sentinel event representing the age at which each core feature developed. 

Of our sample, 262 (83%) were male and average age at diagnosis was 72.5 years (SD= 7.7). RBD developed the earliest with a median onset age of 65.6 years (95% CI: 64.2 to 67.1) in all patients included.  Estimated age of cognitive symptom onset occurred at a median age of 68.5 years (95% CI: 67.6 to 69.8). Parkinsonism developed in 81% of the sample with a median onset age of 72.1 (95% CI: 70.8 to 73.4) and 71% had fluctuations with a similar median onset age of 73.6 (95% CI: 72.8 to 74.7).  The KM survival curves differed significantly between RBD and cognitive symptoms (p=0.017) as well as parkinsonism and fluctuations (p=0.016). VH were present in 63% emerging at a median age of 79.5 years (95% CI: 78.8 to 81.0). 

Our study confirms that RBD is associated with an earlier age of onset relative to the other core features, followed by cognitive changes, parkinsonism, fluctuations and then VH.  

Authors/Disclosures
Parichita Choudhury, MD (Banner Sun Health Research Institute)
PRESENTER
The institution of Dr. Choudhury has received research support from Lewy Body Dementia Association. The institution of Dr. Choudhury has received research support from Arizona Alzheimer's Consortium.
Tanis J. Ferman, PhD (Mayo Clinic Jacksonville) Ms. Ferman has nothing to disclose.
Jonathan Graff-Radford, MD, FAAN Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics.
Jeremiah Aakre, MPH Mr. Aakre has nothing to disclose.
Danielle Brushaber No disclosure on file
David T. Jones, MD (Mayo Clinic) Dr. Jones has received intellectual property interests from a discovery or technology relating to health care.
David S. Knopman, MD, FAAN (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Kejal Kantarci, MD (Mayo Clinic) The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF.
Rodolfo Savica, MD, PhD, FAAN (Mayo Clinic) The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.
Neill R. Graff-Radford, MD, FAAN (Mayo Clinic Jacksonville) The institution of Dr. Graff-Radford has received research support from Biogen. The institution of Dr. Graff-Radford has received research support from Lilly. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Biogen. Dr. Graff-Radford has received publishing royalties from a publication relating to health care.
Daniel A. Drubach, MD, FAAN (Mayo Clinic) No disclosure on file
Julie A. Fields, PhD (Mayo Clinic) The institution of Dr. Fields has received research support from National Institutes of Health. The institution of Dr. Fields has received research support from Patient-Centered Outcomes Research Institute.
Mary M. Machulda, PhD (Mayo Clinic) The institution of Dr. Machulda has received research support from NIH.
Leah K. Forsberg, PhD (Mayo Clinic) Ms. Forsberg has nothing to disclose.
Laura Allen, NP (Mayo Clinic) Ms. Allen has nothing to disclose.
Toji Miyagawa, MD, PhD (Mayo Clinic) Dr. Miyagawa has nothing to disclose.
Otto Pedraza (Mayo Clinic) The institution of Otto Pedraza has received research support from Alzheimer's Association. Otto Pedraza has received publishing royalties from a publication relating to health care.
No disclosure on file
Michael Silber, MB, ChB, FAAN (Mayo Clinic) Dr. Silber has received publishing royalties from a publication relating to health care. Dr. Silber has received personal compensation in the range of $500-$4,999 for serving as a Topic writer with UpToDate.
Walter Kremers The institution of Walter Kremers has received research support from NIH. The institution of an immediate family member of Walter Kremers has received research support from NIH.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Bradley F. Boeve, MD, FAAN (Mayo Clinic) Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.